Skip to content Skip to footer
Subscribe Now
NEWS

Evotec and Plectonic Partner on Next-Generation T-Cell Engagers for Solid Tumors

Shots: Evotec and Plectonic Biotech have entered a research collaboration to explore a novel immunotherapy approach for solid tumors by combining Plectonic’s programmable Logibody technology with Evotec’s BiTco platform Plectonic’s Logibody uses multi-antigen tumor signatures to selectively activate T cells, while Evotec’s BiTco platform uses a non-blocking CD2 antibody to enhance T-cell activity, tumor killing…
September 2, 2026

Read more

NEWS

Styx Biotechnologies Partner with ZoeNCure Therapeutics to Advance ADC Development

Shots: Styx Biotechnologies has entered into a strategic agreement with ZoeNCure Therapeutics to accelerate selected Styx ADC programs toward first-in-human clinical studies for multiple solid tumor indications The collaboration gives Styx a capital-efficient path to advance selected ADC assets through coordinated preclinical, CMC, regulatory & clinical activities while preserving opportunities for global development & strategic partnering As…
September 2, 2026

Read more

EVENTS

Digi-Tech Pharma & AI 2027 | May 11-12 | London, UK

The pharmaceutical and healthcare industries are entering a new era of technology-led transformation, with artificial intelligence, machine learning, data science, informatics, and advanced data management reshaping how medicines are discovered, developed, and delivered. Against this backdrop, Digi-Tech Pharma & AI 2027 will bring together senior professionals, technology leaders, decision-makers, and innovators from the pharmaceutical, biotechnology,…
August 19, 2026

Read more

EXCLUSIVE

Oncolytics Biotech’s Next Chapter: Jared Kelly on Advancing Pelareorep Toward Approval  

Shots  Pelareorep is gaining regulatory momentum through multiple FDA interactions and Fast Track designations, providing greater clarity around potential registration pathways and shaping Oncolytics’ clinical development and partnership strategy.  REO-033 could mark a pivotal step toward registration as the randomized study in RAS-mutant MSS metastatic colorectal cancer builds on encouraging clinical data and has the potential to become…
August 17, 2026

Read more

INSIGHTS+

The US FDA New Drug Approvals in July 2026 

Shots:  The US FDA approved six notable therapies in July 2026 across nephrology, oncology, cardiometabolic disease, ophthalmology, and neuropsychiatry, highlighting continued progress in specialty and chronic disease treatment.   Key approvals included Trutakna (atacicept) for IgA nephropathy, Revtorpyk (gedatolisib) for HR+/HER2- breast cancer, Lipfendra (enlicitide) for hypercholesterolemia, Jideytro (zidesamtinib) for ROS1-positive NSCLC, Lytenava (bevacizumab-vikg) for wet AMD, and Simtriyo (centanafadine) for ADHD, expanding treatment options across diverse patient…
August 11, 2026

Read more

EVENTS

Global Clinical Trials Connect 2027 | May 11-12 | London, UK

As clinical trials become increasingly complex and technology-driven, the need for smarter strategies, stronger collaborations, and patient-centric innovation has never been greater. From decentralized clinical trials and artificial intelligence to advanced data management and evolving regulatory frameworks, the clinical research landscape is undergoing a significant transformation. Global Clinical Trials Connect 2027 aims to bring together…
August 6, 2026

Read more

EVENTS

Global Pharma Partnering Summit 2026 | Nov 2–3, 2026 | Hyderabad, India

The pharmaceutical industry is entering a new era where innovation is no longer driven by individual organisations alone. From drug discovery and clinical research to manufacturing, regulatory compliance, digital transformation, and global commercialisation, success increasingly depends on strategic partnerships that combine expertise, technology, and shared ambition. The Global Pharma Partnering Summit 2026 serves as a…
July 31, 2026

Read more

Astrazeneca and Daiichi-Sankyo New
NEWS

Daiichi Sankyo and AstraZeneca Report CHMP Positive Opinion for Enhertu + Perjeta to Treat HER2-Positive Metastatic Breast Cancer

Shots: The CHMP has recommended Enhertu (5.4mg/kg) + Perjeta for the 1L treatment of pts with HER2+ unresectable or metastatic breast cancer (MBC), backed by P-III (DESTINY-Breast09) trial data (n=1157) Trial assessed Enhertu ± Perjeta vs THP, where it improved PFS by 44% in 383 pts who had not received prior CT or HER2-targeted therapy,…
July 27, 2026

Read more

Load more